Skip to main content
Fig. 4 | Cardiovascular Diabetology

Fig. 4

From: Real-world characteristics, modern antidiabetic treatment patterns, and comorbidities of patients with type 2 diabetes in central and Eastern Europe: retrospective cross-sectional and longitudinal evaluations in the CORDIALLY® study

Fig. 4

Prevalence of A CVD and CKD B types of CVD at baseline (Prescribed Patient Set). *These laboratory values were available for 78.3% (n = 3175) of 4055 patients in the Prescribed Patient Set. Thus, the denominators used to calculate the percentages of patients with CKD according to eGFR and UACR were 3175 (all HCPs), 1493 (endocrinologist group), 1604 (diabetologist group), 78 (cardiologist group). CABG, coronary artery bypass graft; CHF, congestive heart failure; CHF by ECG, CHF confirmed by electrocardiography; CKD, chronic kidney disease. CVD, cardiovascular disease; DPP4i, dipeptidyl peptidase-4 inhibitor; eGFR, estimated glomerular filtration rate; GLP-1 RA, glucagon-like peptide-1 receptor agonist; HCP, healthcare professional; IHD, ischaemic heart disease; MI, myocardial infarction; PAD, peripheral arterial disease; PCI, percutaneous coronary intervention; SGLT2i, sodium-glucose cotransporter-2 inhibitor; UACR, urine albumin-creatinine ratio

Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840